UBS upgraded Alkermes (NASDAQ:ALKS) to Buy from Neutral on Tuesday, citing prospects for Irish biotech’s orexin 2 receptor ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is the second drug candidate ...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the 13 Biotech Stocks with Huge Upside Potential. Jazz Pharmaceuticals plc ...

Low-sodium oxybate (Xywav) reduced blood pressure as expected compared with the higher-sodium version (Xyrem), reduced ...

Suddenly falling asleep mid-sentence, while driving or even passing out without warning is a common scene of comic relief in sitcoms, but for people living with narcolepsy in real life the condition ...

Narcolepsy disrupts more than sleep—it affects daily life. Learn about causes, symptoms, diagnosis, and the latest treatment ...

Narcolepsy is a chronic sleep disorder that makes you feel overwhelmingly tired. Symptoms may include excessive daytime sleepiness, cataplexy, sleep paralysis, hypnogogic hallucinations, disrupted ...

Liblau and Joseph S. Takahashi) This work shows that the amidated terminal ends of the secreted hypocretin (HCRT) peptides (HCRT NH2) are autoantigens in type 1 narcolepsy, an autoimmune disorder ...

Central hypersomnolence disorders, such as narcolepsy type 2 and idiopathic hypersomnia, are associated with reduced health-related quality of life.

4. Participant has a current medical disorder, other than narcolepsy with or without cataplexy, associated with excessive daytime sleepiness (EDS). 5. Participant has current active major depressive ...

Alkermes plc (Nasdaq: ALKS) today announced plans to present new research related to ALKS 2680 at SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking ...